Coronary heart disease in HIV-infected individuals

被引:394
作者
Currier, JS
Taylor, A
Boyd, F
Dezii, CM
Kawabata, H
Burtcel, B
Maa, JF
Hodder, S
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, CHS, Los Angeles, CA 90095 USA
[2] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] Bristol Myers Squibb Co, Princeton, NJ USA
关键词
coronary heart disease; HIV infection; CHD incidence;
D O I
10.1097/00126334-200308010-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is currently unknown whether there is an increased risk of coronary heart disease (CHD) in patients with HIV infection. In addition, the contribution of antiretroviral therapy (ART) to CHD risk has not been quantified. We reviewed administrative claims data for HIV-infected and -uninfected individuals from the California Medicaid population and compared the incidence of and relative risk (RR) for CHD using log-linear regression analyses between groups. The association between exposure to ART and CHD incidence was also assessed. Of 3,083,209 individuals analyzed, 28,513 were HIV-infected. The incidence of CHD among young men (up to age 34) and women (up to age 44) with HIV infection was significantly higher than that among non-HIV-infected individuals. The covariate-adjusted RR for the development of CHD in individuals receiving ART compared with those not receiving ART was 2.06 (P < 0.001) in HIV-infected individuals aged 18-33 years. There were no statistically significant associations between ART exposure and CHD in other age groups. CHD incidence appears accelerated among young HIV-infected individuals. Strategies to reduce CHD risk should be incorporated into HIV primary care.
引用
收藏
页码:506 / 512
页数:7
相关论文
共 24 条
  • [1] [Anonymous], 1988, ARCH INTERN MED, V148, P1023
  • [2] Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
    Bozzette, SA
    Ake, CF
    Tam, HK
    Chang, SW
    Louis, TA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) : 702 - 710
  • [3] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [4] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58
  • [5] Ischemic cardiovascular disease in persons with human immunodeficiency virus infection
    David, MH
    Hornung, R
    Fichtenbaum, CJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 98 - 102
  • [6] FRIISMOLLER N, 2003, 10 C RETR OPP INF FE
  • [7] Obesity, metabolic syndrome, and coronary atherosclerosis
    Grundy, SM
    [J]. CIRCULATION, 2002, 105 (23) : 2696 - 2698
  • [8] Severe premature coronary artery disease with protease inhibitors
    Henry, K
    Melroe, H
    Huebsch, J
    Hermundson, J
    Levine, C
    Swensen, L
    Daley, J
    [J]. LANCET, 1998, 351 (9112) : 1328 - 1328
  • [9] Howard BV, 2002, CIRCULATION, V105, pE128
  • [10] Risk stratification in hypertension: New insights from the Framingham Study
    Kannel, WB
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (01) : 3S - 10S